Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Research

• Publication date

  2018-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-17-1672PMID 29440171PMCID PMC6537867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

  2016cited by this paper
• Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions.

  2016cited by this paper
• Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors

  2016cited by this paper
• Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients

  2016cited by this paper
• Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2

  2016cited by this paper
• A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer

  2016cited by this paper
• Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies

  2015cited by this paper
• Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.

  2015cited by this paper
• Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3

  2015cited by this paper
• Emerging biomarkers in head and neck cancer in the era of genomics

  2015cited by this paper
• A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

  2015cited by this paper
• Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts

  2015cited by this paper
• AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

  2015cited by this paper
• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  2015cited by this paper
• Epidemiology of oral human papillomavirus infection.

  2014cited by this paper
• Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

  2014cited by this paper
• Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

  2014cited by this paper
• miR-24 and miR-205 expression is dependent on HPV onco-protein expression in keratinocytes

  2014cited by this paper
• Characterization of HPV and host genome interactions in primary head and neck cancers

  2014cited by this paper
• Molecular mechanisms of HPV induced carcinogenesis in head and neck.

  2014cited by this paper
• Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines

  2013cited by this paper
• The HPV16 E6 Oncoprotein Causes Prolonged Receptor Protein Tyrosine Kinase Signaling and Enhances Internalization of Phosphorylated Receptor Species

  2013cited by this paper
• mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas

  2012cited by this paper
• PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

  2012cited by this paper
• Cellular Entry of Human Papillomavirus Type 16 Involves Activation of the Phosphatidylinositol 3-Kinase/Akt/mTOR Pathway and Inhibition of Autophagy

  2012cited by this paper
• Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

  2012cited by this paper
• Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

  2012cited by this paper
• Persistence of human papillomavirus infection: keys to malignant progression.

  2011cited by this paper
• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

  2011cited by this paper
• A public genome-scale lentiviral expression library of human ORFs

  2011cited by this paper
• The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer

  2011cited by this paper
• Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

  2011cited by this paper
• The Human Papillomavirus Type 16 E6 Oncoprotein Activates mTORC1 Signaling and Increases Protein Synthesis

  2010cited by this paper
• Human papillomavirus and survival of patients with oropharyngeal cancer.

  2010cited by this paper
• Human papillomavirus oncoproteins: pathways to transformation

  2010cited by this paper
• Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice.

  2010cited by this paper
• COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

  2010cited by this paper
• Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• Oncogenic activities of human papillomaviruses.

  2009cited by this paper
• E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.

  2009cited by this paper
• Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

  2008cited by this paper
• Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.

  2007cited by this paper
• Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysis

  2007cited by this paper
• HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes

  2007cited by this paper
• The PDZ Binding Motif of Human Papillomavirus Type 16 E6 Induces PTPN13 Loss, Which Allows Anchorage-Independent Growth and Synergizes with Ras for Invasive Growth

  2007cited by this paper
• Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein.

  2006cited by this paper
• Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A

  2005cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes.

  2001cited by this paper
• Ubiquitous presence of E6 and E7 transcripts in human papillomavirus—Positive cervical carcinomas regardless of its type

  2000cited by this paper
• The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

  1990cited by this paper
• The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes

  1989cited by this paper
• The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

  1989cited by this paper

• Phosphoinositide dynamics in virus-associated malignancies.

  2025cites this paper
• Human Papilloma Virus does not fully inactivate p53 cellular activity in HNSCC

  2025cites this paper
• Human Papilloma Virus Does Not Fully Inactivate p53 Cellular Activity in HNSCC

  2025cites this paper
• Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma

  2024cites this paper
• Mouse Models for Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy

  2024cites this paper
• Therapeutic strategy for oncovirus-mediated oral cancer: A comprehensive review.

  2023cites this paper
• PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications

  2023cites this paper
• Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review.

  2023cites this paper
• Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review)

  2022cites this paper
• HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer

  2022cites this paper
• Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

  2022cites this paper
• Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine

  2022cites this paper
• Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

  2022cites this paper
• Identification of High-Risk Human Papillomavirus DNA, p16, and E6/E7 Oncoproteins in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas

  2021cites this paper
• MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors.

  2021cites this paper
• Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study

  2021cites this paper
• Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer

  2021cites this paper
• IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer

  2021cites this paper
• Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus–Driven Head and Neck Cancer: Current Evidence and Future Prospects

  2021cites this paper
• Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review

  2021cites this paper
• OTT_A_286024 545..550

  2021cites this paper
• HPV16 E6 promotes cell proliferation, migration, and invasion of human cervical cancer cells by elevating both EMT and stemness characteristics

  2021cites this paper
• Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms

  2020cites this paper
• CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma

  2020cites this paper
• Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma

  2020cites this paper
• Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

  2020cites this paper
• Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinomas: Transcriptional Triggers and Changed Disease Patterns

  2020cites this paper
• Genomic Correlates of Exceptional Response to ErbB3 Inhibition in Head and Neck Squamous Cell Carcinoma.

  2019cites this paper
• mTOR Signalling in Head and Neck Cancer: Heads Up

  2019cites this paper
• Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.

  2019cites this paper
• Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib.

  2019cites this paper
• [Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].

  2019cites this paper
• Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma

  2019cites this paper
• ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

  2019cites this paper
• The AP-1 complex regulates AXL expression and determines sensitivity to PI3Kα inhibition in esophagus and head and neck squamous cell carcinoma

  2018cites this paper
• Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer

  2018cites this paper